The potential applications of T cell receptor (TCR)-like antibody in cervical cancer immunotherapy

References

• InformedHealth.org. Cervical cancer: overview. 2006; 2017 Dec 14 [accessed 2019 Nov 10]. https://www.ncbi.nlm.nih.gov/books/NBK279259/.
   Google Scholar
• WHO. Cervical cancer. 2019 [accessed 2019 Nov 30]. https://www.who.int/cancer/prevention/diagnosis-screening/cervical-cancer/en/.
   Google Scholar
• Denny L, Herrero R, Levin C, Kim JJ. Cervical Cancer In: Gelband H, Jha P, Sankaranarayan R, Horton S, eds. Cancer: Disease Control Priorities. Washington (DC): The International Bank for Reconstruction and Development / The World Bank, 2015:69–84
   Google Scholar
• Mwaka AD, Orach CG, Were EM, Lyratzopoulos G, Wabinga H, Roland M. Awareness of cervical cancer risk factors and symptoms: cross-sectional community survey in post-conflict northern Uganda. Health Expectations. 2016;19(4):854–67. doi:10.1111/hex.12382.
   PubMed Web of Science ®Google Scholar
• Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ. 2001;164:1017–25.
   PubMed Web of Science ®Google Scholar
• Momenimovahed Z, Salehiniya H. Incidence, mortality and risk factors of cervical cancer in the world. Biomed Res Ther. 2017;4(12):1795–811. doi:10.15419/bmrat.v4i12.386.
   Web of Science ®Google Scholar
• Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393(10167):169–82. doi:10.1016/S0140-6736(18)32470-X.
   PubMed Web of Science ®Google Scholar
• Robboy SJ, Anderson MC, Russell P. The etiology of cervical cancer. In: Fu SY, editor. Pathology of the female reproductive tract. London: Churchill Livingstone, Elsevier Science; 2000. p. 146–64
   Google Scholar
• Luria L, Cardoza-Favarato G. Human papillomavirus. StatPearls [Internet]: 2019. [accessed 2020 Jan 20]. https://www.ncbi.nlm.nih.gov/books/NBK448132/.
   Google Scholar
• Braaten KP, Laufer MR. Human papillomavirus (HPV), HPV-related disease, and the HPV vaccine. Rev Obstet Gynecol. 2008;1:2–10.
   PubMedGoogle Scholar
• Woodman CBJ, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2007;7(1):11–22. doi:10.1038/nrc2050.
   PubMed Web of Science ®Google Scholar
• Wang -C-CJ, Palefsky JM. Human papillomavirus (HPV) infections and the importance of HPV vaccination. Curr Epidemiol Rep. 2015;2(2):101–09. doi:10.1007/s40471-015-0039-3.
   PubMedGoogle Scholar
• Yim E-K, Park J-S. The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. Cancer Res Treat. 2005;37(6):319–24. doi:10.4143/crt.2005.37.6.319.
   PubMedGoogle Scholar
• PATE Board. Cervical cancer treatment (PDQ®): patient version. PDQ Cancer Information Summaries 2019; 2020 Jan 10 [accessed 2002 Nov 8]. https://www.ncbi.nlm.nih.gov/books/NBK65985/.
   Google Scholar
• Grace PCY, Paul de S, Levon MK. Current and potential treatments for cervical cancer. Curr Cancer Drug Targets. 2013;13(2):205–20. doi:10.2174/1568009611313020009.
   PubMed Web of Science ®Google Scholar
• Bellati F, et al. Monoclonal antibodies in gynecological cancer: a critical point of view. J Immunol Res. 2011;2011(Article ID 890758):16.
   Google Scholar
• Fujimoto J, Toyoki H, Sato E, Sakaguchi H, Tamaya T. Clinical implication of expression of vascular endothelial growth factor-C in metastatic lymph nodes of uterine cervical cancers. Br J Cancer. 2004;91(3):466–69. doi:10.1038/sj.bjc.6601963.
   PubMed Web of Science ®Google Scholar
• Eskander RN, Tewari KS. Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology. Future Oncol (London, England). 2015;11(6):909–22. doi:10.2217/fon.14.276.
   PubMed Web of Science ®Google Scholar
• Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (gynecologic oncology group 240). Lancet. 2017;390(10103):1654–63. doi:10.1016/S0140-6736(17)31607-0.
   PubMed Web of Science ®Google Scholar
• Heinzerling L, De Toni EN, Schett G, Hundorfean G, Zimmer L. Checkpoint inhibitors. Dtsch Arztebl Int. 2019;116(8):119–26. doi:10.3238/arztebl.2019.0119.
   PubMed Web of Science ®Google Scholar
• Karim R, Jordanova ES, Piersma SJ, Kenter GG, Chen L, Boer JM, Melief CJM, Van der Burg SH. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res. 2009;15(20):6341–47. doi:10.1158/1078-0432.CCR-09-1652.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wu L, Tong R, Yang F, Yin L, Li M, You L, Xue J, Lu Y. PD-1/PD-L1 inhibitors in cervical cancer. Front Pharmacol. 2019;10:65–65. doi:10.3389/fphar.2019.00065.
   PubMed Web of Science ®Google Scholar
• AACR. Pembrolizumab OK’d for cervical cancer. Cancer Discov. 2018;8(8):904.
   Web of Science ®Google Scholar
• Tucker N. FDA grants fast track designation to balstilimab in metastatic cervical cancer. Targeted Oncology; 2020 Apr 8 [accessed 30 May 2020]. https://www.targetedonc.com/view/fda-grants-fast-track-designation-to-balstilimab-in-metastatic-cervical-cancer.
   Google Scholar
• Chen W, Li T, Wang J, Liang L, Huang D, Yan G, Tian Y, Zhang X, Zhang W. Clinical study of nimotuzumab combined with concurrent radiochemotherapy for treatment of locally advanced cervical cancer. Cancer Manag Res. 2019;11:8157–65. doi:10.2147/CMAR.S191134.
   PubMed Web of Science ®Google Scholar
• Cao Y, Deng L, Lian S, Jiang Y. Research on the efficacy of cisplatin and nimotuzumab combined with concurrent chemoradiotherapy on locally advanced cervical cancer. J buon. 2019;24:2013–19.
   PubMed Web of Science ®Google Scholar
• Santin AD, Sill MW, McMeekin DS, Leitao MM, Brown J, Sutton GP, Van le L, Griffin P, Boardman CH. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol. 2011;122(3):495–500. doi:10.1016/j.ygyno.2011.05.040.
   PubMed Web of Science ®Google Scholar
• Hong DS, Concin N, Vergote I, de Bono JS, Slomovitz BM, Drew Y, et al. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. Clinical Cancer Research 2020; 26:1220–8
   PubMed Web of Science ®Google Scholar
• Lheureux S, Butler MO, Clarke B, Cristea MC, Martin LP, Tonkin K, Fleming GF, Tinker AV, Hirte HW, Tsoref D, et al. Association of ipilimumab with safety and antitumor activity in women with metastatic or recurrent human papillomavirus-related cervical carcinoma. JAMA Oncol. 2018;4(7):e173776. doi:10.1001/jamaoncol.2017.3776.
   PubMed Web of Science ®Google Scholar
• Naumann RW, Hollebecque A, Meyer T, Devlin M-J, Oaknin A, Kerger J, López-Picazo JM, Machiels J-P, Delord J-P, Evans TRJ, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II checkmate 358 trial. J Clin Oncol. 2019;37(31):2825–34. doi:10.1200/JCO.19.00739.
   PubMed Web of Science ®Google Scholar
• Rischin D, Gil-Martin M, González-Martin A, Brana I, Hou JY, Cho D, Falchook G, Formenti S, Jabbour S, Moore K, et al. 75P-cemiplimab, a human PD-1 monoclonal antibody, in patients (pts) with recurrent or metastatic cervical cancer: interim data from phase I cohorts. Ann Oncol. 2018;29:x27–x28. doi:10.1093/annonc/mdy487.006.
   Google Scholar
• Papadopoulos KP, Johnson ML, Lockhart AC, Moore K, Falchook GS, Formenti SC, Naing A, Carvajal RD, Rosen LS, Weiss GJ, et al. First-in-human study of cemiplimab alone or in combination with radiotherapy and/or low-dose cyclophosphamide in patients with advanced malignancies. Clin Cancer Res. 2020;26(5):1025. doi:10.1158/1078-0432.CCR-19-2609.
   PubMed Web of Science ®Google Scholar
• Tse K-Y. Avelumab with axitinib in persistent or recurrent cervical cancer after platinum-based chemotherapy (ALARICE); 2019 Feb 18 [accessed 2020 Mar 31]. https://clinicaltrials.gov/ct2/show/NCT03826589#contacts.
   Google Scholar
• Mayadev J, Nunes AT, Li M, Marcovitz M, Lanasa MC, Monk BJ. CALLA: efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study. Int J Gynecol Cancer. 2020;30(7):1065–70. doi:10.1136/ijgc-2019-001135.
   PubMed Web of Science ®Google Scholar
• Roche H-L A phase II, safety, and efficacy study of tiragolumab plus atezolizumab and atezolizumab monotherapy in patients with metastatic and/or recurrent PD-L1−positive cervical cancer (NCT04300647); ClinicalTrials.gov, 2020 [ accessed 2020 July 17]. https://clinicaltrials.gov/ct2/show/NCT04300647#contacts.
   Google Scholar
• Friedman CF, Snyder Charen A, Zhou Q, Carducci MA, Buckley De Meritens A, Corr BR, et al. Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer. Journal for immunotherapy of cancer 2020; 8:e001126.
   PubMed Web of Science ®Google Scholar
• Grau JF, Farinas-Madrid L, Oaknin A. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030). Int J Gynecol Cancer. 2020;30(1):139–43. doi:10.1136/ijgc-2019-000880.
   PubMed Web of Science ®Google Scholar
• Cruz E, Kayser V. Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy. Biologics. 2019;13:33–51.
   PubMed Web of Science ®Google Scholar
• Bharti AC, Singh T, Bhat A, Pande D, Jadli M. Therapeutic strategies for human papillomavirus infection and associated cancers. Front Biosci (Elite Ed). 2018;10(1):15–73. doi:10.2741/e808.
   PubMedGoogle Scholar
• Pal A, Kundu R. Human papillomavirus E6 and E7: the cervical cancer hallmarks and targets for therapy. Front Microbiol. 2020;10:3116–3116. doi:10.3389/fmicb.2019.03116.
   PubMed Web of Science ®Google Scholar
• Áyen Á, Jiménez Martínez Y, Boulaiz H. Targeted gene delivery therapies for cervical cancer. Cancers. 2020;12(5):1301. doi:10.3390/cancers12051301.
   PubMed Web of Science ®Google Scholar
• Kumar S, Biswas M, Jose T. HPV vaccine: current status and future directions. Med J Armed Forces India. 2015;71(2):171–77. doi:10.1016/j.mjafi.2015.02.006.
   PubMedGoogle Scholar
• Nayereh KG, Khadem G. Preventive and therapeutic vaccines against human papillomaviruses associated cervical cancers. Iran J Basic Med Sci. 2012;15:585–601.
   PubMed Web of Science ®Google Scholar
• Barra F, Della Corte L, Noberasco G, Foreste V, Riemma G, Di Filippo C, Bifulco G, Orsi A, Icardi G, Ferrero S, et al. Advances in therapeutic vaccines for treating human papillomavirus-related cervical intraepithelial neoplasia. J Obstetrics Gynaecol Res. 2020;46(7):989–1006. doi:10.1111/jog.14276.
   PubMed Web of Science ®Google Scholar
• Rohaan MW, Wilgenhof S, Haanen J. Adoptive cellular therapies: the current landscape. Virchows Arch. 2019;474(4):449–61. doi:10.1007/s00428-018-2484-0.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8(4):299–308. doi:10.1038/nrc2355.
   PubMed Web of Science ®Google Scholar
• Stoiber S, Cadilha BL, Benmebarek M-R, Lesch S, Endres S, Kobold S. Limitations in the design of chimeric antigen receptors for cancer therapy. Cells. 2019;8(5):472. doi:10.3390/cells8050472.
   PubMed Web of Science ®Google Scholar
• Orbegoso C, Murali K, Banerjee S. The current status of immunotherapy for cervical cancer. Rep Pract Oncol Radiother. 2018;23(6):580–88. doi:10.1016/j.rpor.2018.05.001.
   PubMedGoogle Scholar
• Piersma SJ, Jordanova ES, Van Poelgeest MIE, Kwappenberg KMC, Van der Hulst JM, Drijfhout JW, Melief CJM, Kenter GG, Fleuren GJ, Offringa R, et al. High number of intraepithelial CD8+tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 2007;67(1):354–61. doi:10.1158/0008-5472.CAN-06-3388.
   PubMed Web of Science ®Google Scholar
• Jazaeri A, Gontcharova V, Blaskovich M, Kunkalla K, Masteller E, Fardis M, Chartier C. 873P in vivo persistence of iovance tumour-infiltrating lymphocytes LN-145 in cervical cancer patients. Ann Oncol. 2020;31:S642. doi:10.1016/j.annonc.2020.08.1012.
   Web of Science ®Google Scholar
• Jazaeri AA, Edwards RP, Wenham RM, Matsuo K, Fleming GF, O’Malley DM, Slomovitz BM, Monk BJ, Brown RJ, Suzuki S, et al. A phase 2, multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent cervical carcinoma. J Clin Oncol. 2018;36(15_suppl): TPS5604–TPS5604. doi:10.1200/JCO.2018.36.15_suppl.TPS5604.
   Google Scholar
• Doran SL, Stevanović S, Adhikary S, Gartner JJ, Jia L, Kwong ML, Faquin WC, Hewitt SM, Sherry RM, Yang JC, Rosenberg SA. T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase I/II study. J Clin Oncol. 2019;37(30):2759–68. doi:10.1200/JCO.18.02424.
   PubMed Web of Science ®Google Scholar
• Thommen DS, Schumacher TN. T cell dysfunction in cancer. Cancer Cell. 2018;33(4):547–62. doi:10.1016/j.ccell.2018.03.012.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Liu S, Zhang B, Qiao L, Zhang Y, Zhang Y. T cell dysfunction and exhaustion in cancer. Front Cell Dev Biol. 2020;8:17–17. doi:10.3389/fcell.2020.00017.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015;6(6):e1792–e1792. doi:10.1038/cddis.2015.162.
   PubMed Web of Science ®Google Scholar
• Cheng J, Zhao L, Zhang Y, Qin Y, Guan Y, Zhang T, Liu C, Zhou J. Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies. Front Oncol. 2019;9:1237–1237. doi:10.3389/fonc.2019.01237.
   PubMed Web of Science ®Google Scholar
• Andersen PS, Stryhn A, Hansen BE, Fugger L, Engberg J, Buus S. A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Proc Natl Acad Sci U S A. 1996;93(5):1820–24. doi:10.1073/pnas.93.5.1820.
   PubMed Web of Science ®Google Scholar
• Sela-Culang I, Kunik V, Ofran Y. The structural basis of antibody-antigen recognition. Front Immunol. 2013;4:302–302. doi:10.3389/fimmu.2013.00302.
   PubMed Web of Science ®Google Scholar
• Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol. 2013;31(1):443–73. doi:10.1146/annurev-immunol-032712-095910.
   PubMed Web of Science ®Google Scholar
• Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Helper T cells and lymphocyte activation. In: Molecular biology of the cell. New York: Garland Science; 2002. https://www.ncbi.nlm.nih.gov/books/NBK26827/
   Google Scholar
• Dubrovsky L, Dao T, Gejman RS, Brea EJ, Chang AY, Oh CY, Casey E, Pankov D, Scheinberg DA. T cell receptor mimic antibodies for cancer therapy. OncoImmunology. 2016;5(1):e1049803.
   PubMed Web of Science ®Google Scholar
• Cohen M, Reiter Y. T-cell receptor-like antibodies: targeting the intracellular proteome therapeutic potential and clinical applications. Antibodies. 2013;2(3):517–34. doi:10.3390/antib2030517.
   Google Scholar
• Dass SA, Norazmi MN, Dominguez AA, Miguel MESGS, Tye GJ. Generation of a T cell receptor (TCR)-like single domain antibody (sDAb) against a mycobacterium tuberculosis (Mtb) heat shock protein (HSP) 16kDa antigen presented by Human Leukocyte Antigen (HLA)-A*02. Mol Immunol. 2018;101:189–96. doi:10.1016/j.molimm.2018.07.001.
   PubMed Web of Science ®Google Scholar
• Lai J, Choo JAL, Tan WJ, Too CT, Oo MZ, Suter MA, Mustafa FB, Srinivasan N, Chan CEZ, Lim AGX, et al. TCR–like antibodies mediate complement and antibody-dependent cellular cytotoxicity against Epstein-Barr virus–transformed B lymphoblastoid cells expressing different HLA-A*02 microvariants. Sci Rep. 2017;7(1):9923. doi:10.1038/s41598-017-10265-6.
   PubMed Web of Science ®Google Scholar
• Weidanz JA, Piazza P, Hickman-Miller H, Woodburn D, Nguyen T, Wahl A, Neethling F, Chiriva-Internati M, Rinaldo CR, Hildebrand WH, et al. Development and implementation of a direct detection, quantitation and validation system for class I MHC self-peptide epitopes. J Immunol Methods. 2007;318(1):47–58. doi:10.1016/j.jim.2006.09.019.
   PubMed Web of Science ®Google Scholar
• Dahan R, Tabul M, Chou YK, Meza-Romero R, Andrew S, Ferro AJ, Burrows GG, Offner H, Vandenbark AA, Reiter Y, et al. TCR-like antibodies distinguish conformational and functional differences in two vs. four-domain auto-reactive MHC II-peptide complexes. Eur J Immunol. 2011;41(5):1465–79. doi:10.1002/eji.201041241.
   PubMed Web of Science ®Google Scholar
• He Q, Liu Z, Liu Z, Lai Y, Zhou X, Weng J. TCR-like antibodies in cancer immunotherapy. J Hematol Oncol. 2019;12(1):99. doi:10.1186/s13045-019-0788-4.
   PubMed Web of Science ®Google Scholar
• Høydahl LS, Frick R, Sandlie I, Løset GÅ. Targeting the MHC ligandome by use of TCR-like antibodies. Antibodies (Basel, Switzerland). 2019;8(2):32.
   PubMedGoogle Scholar
• Hammers CM, Stanley JR. Antibody phage display: technique and applications. J Invest Dermatol. 2014;134(2):e17–e17. doi:10.1038/jid.2013.521.
   PubMed Web of Science ®Google Scholar
• Kabir ME, Krishnaswamy S, Miyamoto M, Furuichi Y, Komiyama T. An improved phage-display panning method to produce an HM-1 killer toxin anti-idiotypic antibody. BMC Biotechnol. 2009;9(1):99. doi:10.1186/1472-6750-9-99.
   PubMed Web of Science ®Google Scholar
• Turunen L, Takkinen K, Söderlund H, Pulli T. Automated panning and screening procedure on microplates for antibody generation from phage display libraries. J Biomol Screen. 2009;14(3):282–93. doi:10.1177/1087057108330113.
   PubMedGoogle Scholar
• Trenevska I, Li D, Banham AH. Therapeutic antibodies against intracellular tumor antigens. Front Immunol. 2017;8(1001). doi:10.3389/fimmu.2017.01001.
   PubMedGoogle Scholar
• Jiang T, Shi T, Zhang H, Hu J, Song Y, Wei J, Ren S, Zhou C. Tumor neoantigens: from basic research to clinical applications. J Hematol Oncol. 2019;12(1):93. doi:10.1186/s13045-019-0787-5.
   PubMed Web of Science ®Google Scholar
• Vigneron N. Human tumor antigens and cancer immunotherapy. Biomed Res Int. 2015;2015:948501–948501. doi:10.1155/2015/948501.
   PubMed Web of Science ®Google Scholar
• Wieczorek M, Abualrous ET, Sticht J, Álvaro-Benito M, Stolzenberg S, Noé F, Freund C. Major Histocompatibility Complex (MHC) Class I and MHC class II proteins: conformational plasticity in antigen presentation. Front Immunol. 2017;8(292). doi:10.3389/fimmu.2017.00292.
   Google Scholar
• van Erp EA, Luytjes W, Ferwerda G, Van Kasteren PB. Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease. Front Immunol. 2019;10(548). doi:10.3389/fimmu.2019.00548.
   PubMedGoogle Scholar
• Sergeeva A, He H, Ruisaard K, St John L, Alatrash G, Clise-Dwyer K, Li D, Patenia R, Hong R, Sukhumalchandra P, et al. Activity of 8F4, a T cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo. Leukemia. 2016;30. doi:10.1038/leu.2016.57
   PubMed Web of Science ®Google Scholar
• Wittman VP, Woodburn D, Nguyen T, Neethling FA, Wright S, Weidanz JA. Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death. J Immunol. 2006;177(6):4187. doi:10.4049/jimmunol.177.6.4187.
   PubMed Web of Science ®Google Scholar
• Dubrovsky L, Dao T, Gejman RS, Brea EJ, Chang AY, Oh CY, Casey E, Pankov D, Scheinberg DA. T cell receptor mimic antibodies for cancer therapy. Oncoimmunology. 2015;5(1):e1049803–e1049803. doi:10.1080/2162402X.2015.1049803.
   PubMed Web of Science ®Google Scholar
• Ataie N, Xiang J, Cheng N, Brea EJ, Lu W, Scheinberg DA, Liu C, Ng HL. Structure of a TCR-mimic antibody with target predicts pharmacogenetics. J Mol Biol. 2016;428(1):194–205. doi:10.1016/j.jmb.2015.12.002.
   PubMed Web of Science ®Google Scholar
• Aruna G. Immunotoxins: a review of their use in cancer treatment. J Stem Cells Regen Med. 2006;1:31–36.
   PubMedGoogle Scholar
• Kreitman RJ. Immunotoxins for targeted cancer therapy. Aaps J. 2006;8:E532–E551.
   PubMed Web of Science ®Google Scholar
• Klechevsky E, Gallegos M, Denkberg G, Palucka K, Banchereau J, Cohen C, Reiter Y. Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts. Cancer Res. 2008;68(15):6360–67. doi:10.1158/0008-5472.CAN-08-0928.
   PubMed Web of Science ®Google Scholar
• Epel M, Carmi I, Soueid‐Baumgarten S, Oh S, Bera T, Pastan I, Berzofsky J, Reiter Y. Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies. Eur J Immunol. 2008;38(6):1706–20. doi:10.1002/eji.200737524.
   PubMed Web of Science ®Google Scholar
• Shen Y, Li Y-M, Zhou -J-J, Zhou Z, Xu Y-C, Zhao W-B, Chen S-Q. The antitumor activity of TCR-mimic antibody-drug conjugates (TCRm-ADCs) targeting the intracellular Wilms tumor 1 (WT1) oncoprotein. Int J Mol Sci. 2019;20(16):3912. doi:10.3390/ijms20163912.
   PubMed Web of Science ®Google Scholar
• Kurosawa N, Wakata Y, Ida K, Midorikawa A, Isobe M. High throughput development of TCR-mimic antibody that targets survivin-2B80-88/HLA-A*A24 and its application in a bispecific T-cell engager. Sci Rep. 2019;9(1):9827. doi:10.1038/s41598-019-46198-5.
   PubMed Web of Science ®Google Scholar
• Akatsuka Y. TCR-like CAR-T cells targeting MHC-bound minor histocompatibility antigens. Front Immunol. 2020;11(257). doi:10.3389/fimmu.2020.00257.
   PubMedGoogle Scholar
• Zhang G, Wang L, Cui H, Wang X, Zhang G, Ma J, Han H, He W, Wang W, Zhao Y, et al. Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor. Sci Rep. 2014;4:3571. doi:10.1038/srep03571.
   PubMed Web of Science ®Google Scholar
• Yim E-K, Park J-S. Biomarkers in cervical cancer. Biomark Insights. 2007;1:215–25.
   PubMedGoogle Scholar
• Wentzensen N, von Knebel Doeberitz M. Biomarkers in cervical cancer screening. Dis Markers. 2007;23(4):315–30. doi:10.1155/2007/678793.
   PubMed Web of Science ®Google Scholar
• Suri A, Saini S, Sinha A, Agarwal S, Verma A, Parashar D, Singh S, Gupta N, Jagadish N. Cancer testis antigens: a new paradigm for cancer therapy. Oncoimmunology. 2012;1(7):1194–96. doi:10.4161/onci.20686.
   PubMed Web of Science ®Google Scholar
• Dang E, Yang S, Song C, Jiang D, Li Z, Fan W, Sun Y, Tao L, Wang J, Liu T, et al. BAP31, a newly defined cancer/testis antigen, regulates proliferation, migration, and invasion to promote cervical cancer progression. Cell Death Dis. 2018;9(8):791. doi:10.1038/s41419-018-0824-2.
   PubMed Web of Science ®Google Scholar
• Garg M, Kanojia D, Salhan S, Suri S, Gupta A, Lohiya NK, Suri A. Sperm-associated antigen 9 is a biomarker for early cervical carcinoma. Cancer. 2009;115(12):2671–83. doi:10.1002/cncr.24293.
   PubMed Web of Science ®Google Scholar
• Sarcevic B, Spagnoli GC, Terracciano L, Schultz-Thater E, Heberer M, Gamulin M, Krajina Z, Oresic T, Separovic R, Juretic A, et al. Expression of cancer/testis tumor associated antigens in cervical squamous cell carcinoma. Oncology. 2003;64(4):443–49. doi:10.1159/000070305.
   PubMed Web of Science ®Google Scholar
• Chang AY, Dao T, Gejman RS, Jarvis CA, Scott A, Dubrovsky L, Mathias MD, Korontsvit T, Zakhaleva V, Curcio M, Hendrickson RC. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. J Clin Invest. 2017;127(7):2705–18. doi:10.1172/JCI92335.
   PubMed Web of Science ®Google Scholar
• Spaans VM, Trietsch MD, Peters AAW, Osse M, Ter Haar N, Fleuren GJ, Jordanova ES. Precise classification of cervical carcinomas combined with somatic mutation profiling contributes to predicting disease outcome. Plos One. 2015;10(7):e0133670. doi:10.1371/journal.pone.0133670.
   PubMed Web of Science ®Google Scholar
• Jiang W, Xiang L, Pei X, He T, Shen X, Wu X, Yang H. Mutational analysis of KRAS and its clinical implications in cervical cancer patients. J Gynecol Oncol. 2018;29(1):e4. doi:10.3802/jgo.2018.29.e4.
   PubMed Web of Science ®Google Scholar
• Shen Y, Wei X, Jin S, Wu Y, Zhao W, Xu Y, Pan L, Zhou Z, Chen S. TCR-mimic antibody-drug conjugates targeting intracellular tumor-specific mutant antigen KRAS G12V mutation. Asian J Pharm Sci. 2020;15(6):777–85. doi:10.1016/j.ajps.2020.01.002.
   PubMed Web of Science ®Google Scholar
• Skora AD, Douglass J, Hwang MS, Tam AJ, Blosser RL, Gabelli SB, Cao J, Diaz LA, Papadopoulos N, Kinzler KW. Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes. Proc Natl Acad Sci USA. 2015;112(32):9967–72. doi:10.1073/pnas.1511996112.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Taguchi A, Kawana K, Baba S, Kawata A, Yoshida M, Fujimoto A, Ogishima J, Sato M, Inoue T, et al. Therapeutic significance of targeting survivin in cervical cancer and possibility of combination therapy with TRAIL. Oncotarget. 2018;9(17):13451–61. doi:10.18632/oncotarget.24413.
   PubMedGoogle Scholar
• Vranic S, Cyprian FS, Akhtar S, Al Moustafa A-E. The role of Epstein–Barr virus in cervical cancer: a brief update. Front Oncol. 2018;8(113). doi:10.3389/fonc.2018.00113.
   Google Scholar
• Ahmed M, Lopez-Albaitero A, Pankov D, Santich BH, Liu H, Yan S, Xiang J, Wang P, Hasan AN, Selvakumar A, O’Reilly RJ. TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies. JCI Insight. 2018;3(4):e97805. doi:10.1172/jci.insight.97805.
   PubMed Web of Science ®Google Scholar
• Napoletano C, Bellati F, Tarquini E, Tomao F, Taurino F, Spagnoli G, Rughetti A, Muzii L, Nuti M, Panici PB. MAGE-A and NY-ESO-1 expression in cervical cancer: prognostic factors and effects of chemotherapy. Am J Obstet Gynecol. 2008;198(1):99.e1–7. doi:10.1016/j.ajog.2007.05.019.
   PubMed Web of Science ®Google Scholar
• Holland CJ, Crean RM, Pentier JM, de Wet B, Lloyd A, Srikannathasan V, Lissin N, Lloyd KA, Blicher TH, Conroy PJ, Hock M. Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA. J Clin Invest. 2020;130(5):2673–88. doi:10.1172/JCI130562.
   PubMed Web of Science ®Google Scholar
• Cai S, Han K. Research on expression and importance of p53, p16 and VEGF-C in cervical cancer. J Gynecol Obstet Biol Reprod (Paris). 2015;44(7):639–45. doi:10.1016/j.jgyn.2014.07.012.
   PubMedGoogle Scholar
• Low L, Goh A, Koh J, Lim S, Wang CI. Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen. Nat Commun. 2019;10(1):5382–5382. doi:10.1038/s41467-019-13305-z.
   PubMed Web of Science ®Google Scholar
• Saeed M, Schooten E, Van Brakel M, Cole D, Ten Hagen TLM, Debets R. T cells expressing a TCR-like antibody selected against the heteroclitic variant of a shared MAGE-A epitope do not recognise the cognate epitope. Cancers. 2020;12(5):1255. doi:10.3390/cancers12051255.
   PubMed Web of Science ®Google Scholar
• Kwek ME-J, Kwek J, Lim YH, Lim SL, Wong WL. Metastatic squamous cell carcinoma of the cervix secreting ectopic serum beta human chorionic gonadotropin. 2018.
   Google Scholar
• Neethling FA, Ramakrishna V, Keler T, Buchli R, Woodburn T, Weidanz JA. Assessing vaccine potency using TCRmimic antibodies. Vaccine. 2008;26(25):3092–102. doi:10.1016/j.vaccine.2008.02.025.
   PubMed Web of Science ®Google Scholar
• Luo Q, Zhang S, Wei H, Pang X, Zhang H. Roles of Foxp3 in the occurrence and development of cervical cancer. Int J Clin Exp Pathol. 2015;8:8717–30.
   PubMed Web of Science ®Google Scholar
• Dao T, Mun SS, Scott AC, Jarvis CA, Korontsvit T, Yang Z, Liu L, Klatt MG, Guerreiro M, Selvakumar A, et al. Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody. OncoImmunology. 2019;8(7):e1570778. doi:10.1080/2162402X.2019.1570778.
   PubMed Web of Science ®Google Scholar
• Mathias MD, Sockolosky JT, Chang AY, Tan KS, Liu C, Garcia KC, Scheinberg DA. CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra-low density cancer epitopes. Leukemia. 2017;31(10):2254–57. doi:10.1038/leu.2017.223.
   PubMed Web of Science ®Google Scholar
• Zhou C, Tuong ZK, Frazer IH. Papillomavirus immune evasion strategies target the infected cell and the local immune system. Front Oncol. 2019;9:682–682. doi:10.3389/fonc.2019.00682.
   PubMed Web of Science ®Google Scholar
• Fausch SC, Fahey LM, Da Silva DM, Kast WM. Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation. J Immunol. 2005;174(11):7172–78. doi:10.4049/jimmunol.174.11.7172.
   PubMed Web of Science ®Google Scholar
• Shreya K, Laura MF, Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets. 2007;7(1):79–89. doi:10.2174/156800907780006869.
   PubMed Web of Science ®Google Scholar
• Gonçalves MAG, Donadi EA. Immune cellular response to HPV: current concepts. Braz J Infect Dis. 2004;8:1–9.
   PubMedGoogle Scholar
• Hewitt EW. The MHC class I antigen presentation pathway: strategies for viral immune evasion. Immunology. 2003;110(2):163–69. doi:10.1046/j.1365-2567.2003.01738.x.
   PubMed Web of Science ®Google Scholar
• Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol. 2003;195(3):346–55. doi:10.1002/jcp.10290.
   PubMed Web of Science ®Google Scholar
• Gameiro SF, Zhang A, Ghasemi F, Barrett J, Nichols A, Mymryk J. Analysis of class I major histocompatibility complex gene transcription in human tumors caused by human papillomavirus infection. Viruses. 2017;9(9):252. doi:10.3390/v9090252.
   PubMed Web of Science ®Google Scholar
• Piersma SJ. Immunosuppressive tumor microenvironment in cervical cancer patients. Cancer Microenviron. 2011;4(3):361–75. doi:10.1007/s12307-011-0066-7.
   PubMedGoogle Scholar
• Hallermalm K, Seki K, Wei C, Castelli C, Rivoltini L, Kiessling R, Levitskaya J. Tumor necrosis factor-alpha induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface. Blood. 2001;98(4):1108–15. doi:10.1182/blood.V98.4.1108.
   PubMed Web of Science ®Google Scholar
• Wan S, Pestka S, Jubin RG, Lyu YL, Tsai Y-C, Liu LF. Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells. Plos One. 2012;7(3):e32542. doi:10.1371/journal.pone.0032542.
   PubMed Web of Science ®Google Scholar
• Yang X, Xie S, Yang X, Cueva JC, Hou X, Tang Z, Yao H, Mo F, Yin S, Liu A, et al. Opportunities and challenges for antibodies against intracellular antigens. Theranostics. 2019;9(25):7792–806. doi:10.7150/thno.35486.
   PubMed Web of Science ®Google Scholar
• Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y, Xiang J, Yan S, De Morais Guerreiro MD, Veomett N, et al. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nat Biotechnol. 2015;33(10):1079–86. doi:10.1038/nbt.3349.
   PubMed Web of Science ®Google Scholar
• Lu J, Gu Y, Li Q, Zhong H, Wang X, Zheng Z, Hu W, Wen L. Wilms’ tumor 1 (WT1) as a prognosis factor in gynecological cancers: a meta-analysis. Medicine. 2018;97(28):e11485–e11485. doi:10.1097/MD.0000000000011485.
   PubMed Web of Science ®Google Scholar
• Lowe DB, Bivens CK, Mobley AS, Herrera CE, McCormick AL, Wichner T, Sabnani MK, Wood LM, Weidanz JA. TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targets. mAbs. 2017;9(4):603–14. doi:10.1080/19420862.2017.1302630.
   PubMed Web of Science ®Google Scholar
• Zhu X, Belmont HJ, Price-Schiavi S, Liu B, Lee H-I, Fernandez M, Wong RL, Builes J, Rhode PR, Wong HC, et al. Visualization of p53 264–272/HLA-A*0201 complexes naturally presented on tumor cell surface by a multimeric soluble single-chain T cell receptor. J Immunol. 2006;176(5):3223–32. doi:10.4049/jimmunol.176.5.3223.
   PubMed Web of Science ®Google Scholar
• He Q, Jiang X, Zhou X, Weng J. Targeting cancers through TCR-peptide/MHC interactions. J Hematol Oncol. 2019;12(1):139. doi:10.1186/s13045-019-0812-8.
   PubMed Web of Science ®Google Scholar
• Chang AY, Gejman RS, Brea EJ, Oh CY, Mathias MD, Pankov D, Casey E, Dao T, Scheinberg DA. Opportunities and challenges for TCR mimic antibodies in cancer therapy. Expert Opin Biol Ther. 2016;16(8):979–87. doi:10.1080/14712598.2016.1176138.
   PubMed Web of Science ®Google Scholar
• Krausa P, Iii MB, Savage D, Hui KM, Bunce M, Ngai JLF, Teo DLT, Ong YW, Barouch D, Allsop CEM, et al. Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations. Tissue Antigens. 1995;45(4):223–31. doi:10.1111/j.1399-0039.1995.tb02444.x.
   PubMedGoogle Scholar
• Li D, Toji S, Watanabe K, Torigoe T, Tsukahara T. Identification of novel human leukocyte antigen-A*11:01-restricted cytotoxic T-lymphocyte epitopes derived from osteosarcoma antigen papillomavirus binding factor. Cancer Sci. 2019;110(4):1156–68. doi:10.1111/cas.13973.
   PubMed Web of Science ®Google Scholar
• Maciag PC, Schlecht NF, Souza PS, Franco EL, Villa LL, Petzl-Erler ML. Major histocompatibility complex class II polymorphisms and risk of cervical cancer and human papillomavirus infection in Brazilian women. Cancer Epidemiol Biomarkers Prev. 2000;9(11):1183.
   PubMed Web of Science ®Google Scholar
• Dass SA, Norazmi MN, Acosta A, Sarmiento ME, Tye GJ. TCR-like domain antibody against mycobacterium tuberculosis (Mtb) heat shock protein antigen presented by HLA-A*11 and HLA-A*24. Int J Biol Macromol. 2020;155:305–14. doi:10.1016/j.ijbiomac.2020.03.229.
   PubMed Web of Science ®Google Scholar
• Garrido F. MHC/HLA class I loss in cancer cells. Adv Exp Med Biol. 2019;1151:15–78.
   PubMed Web of Science ®Google Scholar